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Liver disease in recipients of long-functioning renal allografts. After
noting that hepatic failure was the leading cause of death in our
transplant recipients whose renal allografts had functioned for more
than five years, we reviewed retrospectively the post-transplant course
of these patients to assess the long-term effect of liver disease in this
population. Sufficient data was available to evaluate 184 of 217 long-
term survivors (85%). Twenty-six patients (14%) experienced a dou-
bling of SGOT and/or SGPT of greater than six months' duration and
were defined as having chronic liver disease. The etiology of chronic
liver disease was identified in 14 patients (54%), of whom 11 were
HB5Ag positive. Evidence of chronic hepatitis developed in only six of
26 patients (22%) during the first four years post transplant. Once
enzyme abnormalities occurred, they were unremitting until death or
end of the study in 73% of patients, Actuarial survival of patients with
chronic liver disease was markedly decreased compared to long-
surviving transplanted controls. Ten of the 12 deaths in patients with
hepatocellular abnormalities were due to hepatic failure, of which eight
occurred in the setting of extrahepatic sepsis. Chronic liver disease is a
late complication of transplantation and is associated with significant
mortality due to an increased susceptibility to overwhelming sepsis.
Maladie hépatique chez les receveurs d'allogreffe rénale ayant une
fonction prolongée. Après avoir constaté que l'insuffisance hépatique
était Ia principale cause de mortalité chez nos patients transplantés chez
lesquels les allogreffes rénales avaient fonctionné pendant plus de 5 ans,
nous avons étudié de facon retrospective l'évolution de ces patients
aprés la transplantation, afin de determiner les consequences a long
terme de la maladie hCpatique dans cette population. Des donnCes
suffisantes ont eté obtenues chez 184 de 217 survivants a long terme
(85%). 36 patients (14%) ont eu un doublement des SGOT et/ou des
SGPT durant plus de six mois et ont etC défini comme ayant une maladie
hCpatique chronique. La cause de la maladie hCpatique chronique a etC
identifiée chez 14 patients (54%) parmi lesquels 11 étaient antigène HBs
positif. Des cas d'hepatique chronique sont apparu chez seulement 6
des 26 patients (22%) pendant les quatre premiCres annCes aprCs Ia
greffe. Une fois apparues, les anomalies enzymatiques persistaient
jusqu'à Ia mort ou a Ia fin de l'étude chez 73% des patients. La survie
actuarielle des patients avec une maladie hCpatique chronique Ctait
notablement diminuCe comparee avec les transplantes de longue date
servant de contrôle. Dix morts sur douze chez les patients ayant des
anomalies hCpato-cellulaires ont etC dtìs a l'insuffisance hCpatique,
parmi lesquels 8 sont survenues au cours d'une infection extra-
hépatique. Une atteinte hCpatique chronique est une complication
tardive de Ia transplantation qui est associée avec une mortalité
importante due a une augmentation importante de la susceptibilité a
l'infection.
Multiple retrospective studies during the past decade have
identified chronic liver disease as a significant source of mor-
bidity and mortality in renal transplant recipients [1—4]. Most of
these studies have focused upon the early post-transplant
period and lack long-term follow-up. However, recent data
from this institution have identified chronic liver disease as the
leading cause of late mortality among recipients bearing long-
surviving renal allografts, prompting this more detailed review
of liver disease in this group of patients [4].
Patients with chronically abnormal liver function studies,
with or without hepatitis B surface antigememia, may experi-
ence prolonged allograft function, but also have a high rate of
mortality from non-hepatic infection [3, 5, 6]. Suggested expla-
nations for these observations include an acquired im-
munodeficiency secondary to chronic liver disease and differ-
ences in HLA phenotypes of graft recipients, which may either
predispose them to acquiring the unknown hepatitic agent or
interfere with its subsequent clearing [3, 7].
The etiology of chronic liver disease in renal transplant
patients is enigmatic. In contrast to data from many European
transplant centers, the incidence of hepatitis B surface antigen
carriage in prospective allograft recipients in the United States
is quite low (<5%) [8]. Nonetheless, a significant proportion of
such individuals when transplanted have persistently abnormal
liver function studies (6 to 16%), suggesting that factors unre-
lated to hepatitis B virus are responsible [1, 9—11]. Indeed, with
decreased transmission of hepatitis B virus resulting from
improved blood banking techniques, it is likely that other
serologically transmitted agents, like the non-A, non-B hepatitis
virus(es), is (are) involved in the majority of cases of transplant-
associated chronic liver disease, despite inadequate techniques
for isolating this agent(s) or detecting its presence in the
diseased host [12—14]. Other possible etiologic agents include
adenovirus, cytomegalovirus, Epstein-Barr virus, herpes sim-
plex virus, and varicella-zoster virus, and the potentially hepato-
toxic drugs, azathioprine and alpha-methyldopa [1, 3, 15—19].
To determine which patients with long-functioning renal
allografts are at risk for morbidity and mortality from liver
disease, we have evaluated retrospectively the cause and inci-
dence of both transient and chronic abnormalities in liver
function in recipients of renal allografts functioning more than
five years.
Methods
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The renal transplant experience of the Brigham and Women's
Hospital (formerly the Peter Bent Brigham Hospital) between
March, 1951, and January, 1976, was reviewed. During this
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Table 1. Epidemiologic differences and causes of end-stage kidney disease in recipients of long-term renal allografts
Normal liver function studies
(N = 158 patients)
Abnormal liver function
studies (N = 26 patients) Statistical significance
Epidemiologic Differences
Age, years
Sex, male/female
Type of transplant, living related/cadaveric
Dialysis prior to transplant, months
32.9 12.1
91/67
108/50
12.8 10.5
34.1 10.5
19/7
2 1/6*
9.3 5.2
NS
NS
NS
NS
Causes of end-stage kidney disease
85 (53.8%)
28 (17.7%)
14 (8.9%)
7 (4.4%)
7 (4.4%)
3 (1.9%)
3 (1.9%)
9 (5.7%)
12 (46.2%)
4 (15.4%)
3 (11.5%)
2 (7.7%)
2 (7.7%)
2 (7.7%)
0
0
NS
NS
NS
NS
NS
NS
NS
NS
Chronic glomerulonephritis
Chronic tubulointerstitial nephritis
Polycystic kidney disease
Congenital disorders
Unknown
Hypertension
Diabetes mellitus
Other
*One patient had one living-related and one cadaveric transplant.
period, 535 patients received 589 kidney transplants, 217 of
which had functioned more than five years. The data for this
study were obtained from hospital records, transplant clinic
charts, surgical records, and, when needed, from contact with
referring nephrologists. The clinical history and physical exam-
ination, medications taken, intercurrent illnesses, hospitaliza-
tions, and laboratory and serologic evaluations were examined
and recorded for each patient. Follow-up data through Decem-
ber, 1982, were available on 184 of these individuals, who are
the basis of this study. Excluded from this analysis were
patients who did not have at least biannual biochemical deter-
minations of liver function, usually SGOT, SGPT, alkaline
phosphatase, and biirubin. These determinations were also
performed routinely during evaluations of fever and the major-
ity of hospitalizations. Details of clinical management and use
of immunosuppression have been reported previously [4, 20].
One hundred sixty-eight patients were tested for hepatitis B
surface antigen prior to transplant; an additional 16 patients
were noted to be hepatitis B surface antigen negative within
four years of transplantation. Thirty-six individuals had simul-
taneous pretranspiant hepatitis B surface antibody and antigen
determinations. Serologic testing for carriage of hepatitis B
virus was repeated at various intervals throughout the trans-
plant course, and at the onset of every acute episode of hepatic
dysfunction. Determinations of hepatitis B surface antigen were
first performed in 1967 via the agar gel diffusion method. In
1970, counterimmunoelectrophoresis replaced the original
method until late 1973, when radioimmunoassay testing was
initiated; each new technique was substantially more sensitive
than those used previously [21].
Chronic hepatitis was defined as a twofold elevation of SGOT
and/or SGPT of greater than six months' duration. Chronic
alcohol abuse was defined as the steady ingestion of greater
than one pint of alcohol daily for more than one year's duration.
Chronic renal allograft rejection was defined by the renal biopsy
presence of humoral and/or cellular immune-mediated damage.
Prior to 1967 normal values of SGOT were 13 to 29 Karmen
Units; from 1976 to 1980, 8 to 33 Karmen Units, and from 1980
to 1982, 22 to 47 International Units/liter. Normal values of
SGPT have consistently been 5 to 35 International Units/liter.
Clinical evaluation of patients thought to have hepatitis in-
cluded a search for potential hepatotoxic drugs, radiologic and
ultrasonographic evaluation, and viral serologies if fever was
noted. Liver biopsies were performed at the discretion of the
attending physician on service at the time.
Independent samples proportions tests and t tests were used
to compare variables. Actuarial survival curves were con-
structed with Kaplan-Meier methods and analyzed with the
Z-test.
Results
Twenty-six of the 184 patients (14%) developed chronic
twofold elevation of hepatocellular enzymes, an average of 7
(MST SD = 7.0 4.4 yr) years posttransplant and were
defined as having chronic liver disease. Only six of these 26
patients (22%) developed any abnormalities during the first four
years post transplant. Moreover, once the liver enzymes be-
came elevated, they remained abnormal until death or the end
of the study in 73% of patients.
Epidemiologic variables and causes of end-stage
renal disease
The age, sex, duration of hemodialysis prior to transplant,
and type of transplant in each group were assessed. As evi-
denced in Table 1, there were minor differences between
groups, which did not reach statistical significance by the
independent samples proportions test or t tests.
The cause of end-stage renal disease and secondary medical
complications were evaluated in the 26 patients with chronic
hepatocellular abnormalities and in the 158 patients with normal
hepatic function.
As depicted in Table 1, the major causes of renal failure in
each group were chronic glomerulonephritis and tubulointer.
stitial nephritis. There were only three diabetics in the normal
liver function study group and none in the chronically abnormal
liver function study group. There were no statistical differences
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Normal liver function studies
(N 158 patients)
Abnormal liver function
studies (N = 26 patients) Statistical significance
Hypertension 70 (44.3%) 15 (57.7%) NS
Cataracts 41 (25.9%) 4 (15.4%) NS
Urinary tract infection 29 (18.4%) 2 (7.7%) NS
Avascular necrosis 22 (13.9%) 11(42.3%) P = 0.0005
Infection 22 (13.9%) 5 (19.2%) NS
Malignancy 21(13.3%) 5 (29.2%) NS
Anemia 14 (8.9%) 2 (7.7%) NS
Diabetes mellitus 8 (5.1%) 2 (7.7%) NS
Myocardial infarction 6 (3.8%) 0 NS
Peptic ulcer disease 6 (3.8%) 1 (3.8%) NS
Time post transplant, years
Fig. 1. Depiction of markedly decreased actuarial survival of long-
surviving transplant recipients with chronic liver disease ( ) as
compared to long-surviving transplanted controls without liver enzyme
abnormalities (—). P = 0.004.
between the groups for cause of renal failure using the indepen-
dent samples proportions test.
Secondary medical complications
Table 2 lists the secondary medical complications in each
group. Hypertension was the most common complication.
Avascular necrosis, malignancy, and infections (other than the
urinary tract) were seen more commonly in the group with
chronic liver enzyme abnormalities, whereas cataracts and
urinary tract infections were more frequent in the normal liver
function study group. None of these differences achieved
statistical importance by the independent samples proportions
test, except for the higher incidence of avascular necrosis in the
chronic hepatitis group.
Mortality
As evidenced by Kaplan-Meier survival curves, patients with
chronic liver disease had a markedly decreased actuarial sur-
vival when compared to patients without elevated liver en-
zymes (Fig. 1). The difference between the curves was shown to
be highly significant (P = 0.004) using the Z-test. Thus, twelve
of the 26 patients (48%) with chronic liver disease died, an
average of 4.6 3.5 years after developing elevated liver
enzymes. Ten died of hepatic insufficiency, eight of whom with
associated extrahepatic sepsis, and two died from non-hepatic
causes. The etiologies of extrahepatic sepsis were polymicro-
bial in three cases: Pseudomonas aeruginosa and
Staphylococcus aureus, Streptococcus faecalis and Listeria
monocytogenes, Staphylococcus aureus and Bacteroides
fragilis. The other five terminal septic events had Escherichia
coli, Staphylococcus aureus, Candida albicans [2] and an
unknown as the sources. No patients with normal liver function
studies died from liver disease or related complications.
Five of 11 (45%) chronically hepatitis B antigen-positive
patients with chronic hepatocellular enzyme elevations died
during the study, whereas none of nine chronically antigenemic
patients with normal liver enzymes died. Seven of 15 (47%)
patients who were seronegative for hepatitis B antigen, but had
chronically elevated liver function studies, died during the
study interval.
Hepatocellular enzyme findings
There were no statistical differences between levels of SGOT
and SGPT in patients who died versus those who are alive, or
between hepatitis B surface antigen-positive and antigen-neg-
ative patients in terms of magnitude of hypertransaminasemia.
Chronic hyperbilirubinemia was unusual, only occurring in
three individuals, one of whom had presumed hereditary
spherocytosis; this patient is still alive, but the other two died of
hepatic failure. The development of acute hyperbilirubinemia
predicted a fatal outcome in eight of nine patients within a few
weeks.
Pre-1970 incidence of chronic liver disease
Twelve of the 50 patients transplanted before 1970 developed
chronically elevated hepatocellular enzymes, of whom five died
(41.7%). Fourteen of 134 patients transplanted during 1970 and
later developed chronically abnormal liver enzymes, -of whom
seven died (50.0%). There was no statistical difference in age,
sex, mortality rate, incidence of hepatitis B antigenemia, or
duration of transplant function in each group. However, there
was a statistically higher incidence (P = 0.018) of chronically
abnormal hepatocellular enzymes in the group transplanted
before 1970. Actuarial survival curves, constructed with Kap-
lan-Meier methods, revealed no difference in the two groups (P
= 0.13).
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Coexistent renal disease
Ten of the 26 patients had progressive elevation of their
serum creatinine to greater than 2.4 mg%. Six of the patients
had renal biopsy specimens with pathologic evidence of mild to
moderate lymphocytic infiltration. Two of these six also had
humoral evidence of rejection with vascular changes, while two
others had mild glomerulitis. The other four patients had no
histologic specimens available. Eight of these ten patients died,
of whom five succumbed from extrahepatic sepsis and liver
failure.
Etiology of chronic liver disease
The cause of chronic liver disease was defined in only 14 of 26
patients (54%), 11 of whom were hepatitis B surface antigen
positive. Only four of the 16 chronically positive hepatitis B
carriers who seroconverted posttransplant had temporally re-
lated blood transfusions and/or surgery as a possible source of
antigenemia. Three of these antigen-positive patients were also
chronic alcoholics, as were two other hepatitis B surface
antigen-negative patients. Four individuals had transient in-
creases in cytomegalovirus (CMV) titers, two of whom were
hepatitis B surface antigen positive, and one of whom was a
known alcoholic. One patient had a history of pancytopenia
with myeloid metaplasia. No overt cause for liver disease could
be identified in the remaining 12 patients. All five of the chronic
alcohol abusers died during the study. Excluding these deaths,
there was no difference in mortality rate between patients with
known and unknown causes of liver disease.
Liver histology
Eleven histologic specimens of liver tissue were available
from ten of the 26 patients with chronic liver disease. Six were
biopsy specimens and five were obtained at autopsy. The
duration of hepatocellular enzyme elevation in these ten pa-
tients prior to hepatic histologic examination was 32.4 21.9
months. Six patients had histologic evidence of either
macronodular or micronodular cirrhosis, three of whom also
had evidence of chronic active hepatitis. All of these patients
died of hepatic failure and its complications. Two other patients
had patchy hepatocyte necrosis, predominantly in the
centrilobular area; one of these patients also had heavy iron
deposition. The final two patients had evidence of portal and
periportal fibrosis with a sparse inflammatory infiltrate. Of these
ten patients, three had presumptive causes for chronic liver
disease—two were chronic ethanol abusers and one was hepa-
titis B antigen positive. All three developed micronodular
cirrhosis and/or chronic active hepatitis and subsequently died.
Coexistent use of potentially hepatotoxic drugs
Potentially hepatotoxic drugs were used in all of the trans-
plant patients. Azathioprine was used for maintenance im-
munosuppression chronically at a dose of approximately 2
mg/kg/day. At five years posttransplant, the mean dose of
azathioprine of the 184 patients as a group was 121.6 43.2
mg/day. In the 26 patients with chronic hepatocellular enzyme
elevations, the mean dose of azathioprine was reduced to 62.5
44.3 mg/day (including five patients who had azathioprine
stopped altogether or were switched to cyclophosphamide)
after development of the chronic liver enzyme abnormalities.
Of 13 patients who had at least a 50% reduction in their baseline
azathioprine dose after developing liver enzyme elevations, six
died. Similarly, a group of 13 patients who either had minimal or
no change in azathioprine dose after developing chronic liver
enzyme abnormalities had six fatalities. Only two patients had
a sustained normalization of hepatocellular enzymes with re-
duction in azathioprine dosage, whereas one patient had sus-
tained liver enzyme reduction with no change in daily
azathioprine dose.
Of the 158 patients with normal liver function, thirty were
treated intermittently with alphamethyldopa, seven with
isoniazid and one with rifampin. Of the 26 patients with
abnormal liver function, only three received alpha-methyldopa
and none received anti-tuberculous medications.
Hepatitis B virus carrier state
Twenty of the 184 patients (11%) were identified as carriers of
the hepatitis B virus, of whom 11(55%) developed chronic liver
disease. Sixteen of these 20 patients (80%) acquired the hepa-
titis B surface antigen after transplantation. Only two of these
patients could have acquired the antigen pre transplantation due
to lack of availability of screening tests, but one of these two
patients had a temporally related seroconversion after several
red cell transfusions later in his transplant course. Of the four
patients who were hepatitis B antigen positive prior to trans-
plantation, two developed chronic liver disease and one died.
All twenty patients have remained persistently antigenemic,
and only two have developed hepatitis B surface antibody.
However, an additional six patients known to be hepatitis B
antigen and antibody negative at the time of transplantation
have developed antibody post transplantation.
Discussion
The present study was undertaken after we found that hepatic
failure was the leading cause of death in transplant recipients
whose allogralts had functioned for at least five years, and that
accompanying extrahepatic sepsis was part of the terminal
event in 80% of these patients [4]. Although several retrospec-
tive studies have reviewed the effects of chronic liver disease
and hepatitis B antigenemia on patient and renal allograft
survival, most have evaluated only the early post-transplant
period [1—3]. The data reported here confirm that chronic liver
disease also significantly decreases survival in patients with
long-functioning renal allografts. No other adverse prognostic
factors were statistically capable of explaining the significant
difference in survival between the long-term allograft survivors
with and without chronic liver disease.
The hepatitis B virus was the most common identifiable cause
of chronic liver disease in this study. The majority (80%) of the
hepatitis B antigen-positive patients first revealed evidence of
the carrier state after transplantation. Moreover, 55% of the
antigenemic transplant recipients developed clinical or bio-
chemical evidence of liver disease. This figure may underesti-
mate the true risk of liver disease, as others have demonstrated
the presence of progression of liver disease on biopsy in the
absence of biochemical or clinical evidence [22, 23]. Of con-
cern, 45% of HBsAg-positive patients with chronic liver disease
died during the study. Ethanol was the other major etiologic
agent of chronic liver disease identified in this study, and was
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associated with 100% mortality. In the remaining patients, the
etiology of the liver disease was not identified.
With the advent of counterimmunoelectrophoresis for hepa-
titis B antigen testing in 1970, a significant advance in detecting
the hepatitis B virus was made. Our retrospective evaluation
demonstrated a significantly higher incidence of chronic liver
disease in the pre-1970 long-surviving transplant population that
was only partially related to a higher incidence of hepatitis B
antigen carriage. Perhaps this was related to more liberal red
cell transfusion therapy in the 1960's, thus propagating the
spread of hepatitis viruses via a serological route. However,
there did not appear to be any difference from a statistical
standpoint in the pre- or post-1970 chronic liver disease groups
when considering age, sex, incidence of hepatitis B antigenem-
ia, and actuarial survival.
The high incidence of lethal sepsis occurring in the setting of
chronic liver disease late after transplantation is striking in this
and other studies [3]. This predilection for sepsis has been
attributed to an additional immunosuppressive effect of liver
disease itself; an increase in the suppressor-cytotoxic subset of
T lymphocytes with a concomitant decrease in the helper-
inducer subset has been observed among non-immunosup-
pressed patients with presumed non-A, non-B hepatitis or with
cytomegalovirus infection [3, 24]. Although some workers note
an increase in early renal allograft survival in transplant recip-
ients who have chronic hepatocellular enzyme elevations [5],
38% of our patients sustained progressive elevations in serum
creatinine, regardless of whether they were hepatitis B surface
antigen positive or negative. Thus, the apparent acquired im-
munodeficiency of chronic liver disease would appear not to
prevent late deterioration of renal allograft function. It is also
possible, however, that the cause(s) of liver disease or the liver
disease itself could be the source for immune damage to the
kidney. Two patients did have a mild glomerulitis that could
have been related to the above factors. In addition, 80% of the
patients with both chronic liver disease and worsened renal
function died, all but three from sepsis. The combined im-
munosuppressive effects of liver disease and azotemia would
appear to predispose these patients to infection.
Patients with end-stage renal disease, when infected with
hepatitis B virus, mount weak immune reactions to the virus,
have difficulty clearing the antigen, and tend to manifest a
prolonged, anicteric disease with aminotransferase levels under
1,000 Karmen Units [25—27]. None of the individuals in our
study was capable of clearing the hepatitis B surface antigen,
and aminotransferase levels were rarely above 400 Karmen
Units. In contrast, patients with intact immune systems usually
develop hepatitis B surface antibody and an acute icteric
disease with significantly elevated aminotransferase levels [25,
27]. Thus, prolonged exposure to hepatitis B virus or other
hepatitic agents may predispose immunologically compromised
patients toward the development of chronic liver disease.
Moreover, as the magnitude of enzyme elevation was rarely
more than three- to fourfold above the upper limits of normal,
the disease process is low grade and may not lead to clinical
liver dysfunction for many years.
The impact of chronic liver disease on late morbidity and
mortality in recipients of long-functioning renal allografts also
raises questions about transfusion policies that expose patients
to the risk of hepatitis viruses. While such transfusions clearly
increase early graft survival, their role in later morbidity and
mortality has not been assessed. The continuing decline in
actuarial patient survival more than five years after transplant
caused by chronic liver disease suggests a need for such an
evaluation.
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